NovoRapid (Insulin Aspart)

Insulin Aspart (brand name NovoRapid, NovoLog in the US) is a rapid-acting insulin analogue. Compared to human insulin, the amino acid proline at position B28 is replaced by aspartic acid. That single change weakens the molecule's tendency to assemble into hexamers.

The effect only shows up in the subcutaneous depot: human insulin first has to break down from its hexamers before it can enter the bloodstream, and that breakdown costs time. Insulin aspart skips most of it and is absorbed considerably faster. At the insulin receptor itself it behaves like endogenous insulin.

This information is for research and educational purposes only. No medical advice.

At the receptor, insulin aspart is no different from endogenous insulin. It drives glucose uptake into muscle and fat cells by moving GLUT4 transporters to the cell surface, slows hepatic glucose production, inhibits lipolysis in adipose tissue and promotes amino acid uptake.

The entire difference from human insulin therefore lies not in the kind of effect but in its timing. That is by design: the analogue was developed to mimic the natural insulin rise after a meal more closely than unmodified human insulin can.

With a rapid-acting insulin the time profile, not the potency, is the property that actually matters:

• Onset: 10 to 20 minutes after subcutaneous administration.
• Peak: 1 to 3 hours.
• Duration: 3 to 5 hours.

Home et al. measured a peak serum level at a mean of 52 minutes in healthy volunteers in 1999, versus 145 minutes for human insulin, at more than twice the peak value. Total bioavailability was identical. So it is the same amount of effect, merely compressed into a shorter and steeper window.

One detail easily missed when reading these studies: the underlying clamp experiments ran under continuous glucose infusion. The hypoglycemia the same dose would have caused without that safeguard was continuously counteracted. The published curves show the effect profile, not the risk profile.

Mudaliar et al. showed the same year that the profile is broadly preserved across abdomen, thigh and upper arm, though duration is shorter after abdominal administration.

The risk with insulin does not come from an unexpected side effect but from the main effect: blood glucose falls reliably and dose-proportionally, and it does not stop once a safe value is reached.

• Early signs: tremor, sweating, palpitations, intense hunger, nervousness.
• Advanced: impaired concentration, slurred speech, confusion, aggressive or slowed behavior.
• Severe: seizure, unconsciousness, death.

The treacherous part is the order: cognitive impairment sets in precisely when independent corrective action would be required. Someone already confused generally cannot help themselves anymore.

Three points follow from this regardless of any dose: fast-acting carbohydrates (glucose tablets, juice, sugared drinks) must be within reach before administration, not in a cupboard. Without a blood glucose meter there is no objective feedback on the current value. And never alone: without a second person present, the only safeguard that still works during incapacitation is missing. Because of the 3 to 5 hour duration, hypoglycemia can recur after an initial improvement, so a single dose of sugar does not cover the window.

Alcohol suppresses hepatic gluconeogenesis and thereby disables the body's own counter-regulation. Physical exertion further increases glucose uptake. Both amplify the effect considerably and unpredictably. With confusion or clouded consciousness, calling emergency services is the only correct response.

An effect often overlooked next to hypoglycemia: insulin transports potassium from the extracellular space into cells. Serum potassium falls as a result, without any change in total body stores.

Engebretsen et al., in their review of high-dose insulin administration, list hypoglycemia and hypokalemia as the two principal risks. Pronounced hypokalemia can trigger cardiac arrhythmias.

One practical point matters most here: this risk runs independently of blood glucose. Catching a hypoglycemic episode with carbohydrates does not correct the potassium shift.

In the comparison trial by Home, Lindholm and Riis (2000) across 1070 adults with type 1 diabetes over six months, insulin aspart was slightly superior to human insulin for long-term blood glucose control. Post-meal values were lower and severe nocturnal hypoglycemic events occurred less often (1.3 versus 3.4 percent of patients). Mathiesen et al. (2007) confirmed the safety profile in a randomized comparison across 322 pregnant women with type 1 diabetes.

For contexts outside diabetes therapy, a different paper is more informative. Ip et al. surveyed 41 non-diabetic insulin users from the strength-training community in 2012: 56.8 percent reported hypoglycemia, one participant reported loss of consciousness. That was a self-selected group who considered the substance manageable.

• Hypoglycemia: the central, dose-limiting risk, see its own section above.
• Hypokalemia: from intracellular potassium shift, with potential for cardiac arrhythmias.
• Injection site reactions: redness, swelling, itching.
• Lipohypertrophy: with repeated injection into the same region. Absorption from such areas becomes unpredictable, which further raises the dosing risk. Rotate injection sites accordingly.
• Sodium and water retention: edema, mainly at the start of use.
• Allergic reactions: rarely documented.

Insulin is dosed in International Units, not in ml or mg. At 100 IU per ml, a few scale marks correspond to a substantial amount of active substance. Using a syringe not calibrated for U-100 is a documented cause of severe overdose.

Store unopened in the fridge at 2 to 8 degrees, away from the freezer compartment, and do not freeze. Insulin that has been frozen is unusable and gets discarded, even if it looks normal after thawing.

Units in use are usually no longer refrigerated and are used up within about four weeks, protected from light and from temperatures above 30 degrees.

Insulin aspart is a clear, colorless solution. Cloudiness, discoloration or visible particles mean: discard, do not use. Keep out of reach of children.